


1644



TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	09/583200
Filing Date	May 30, 2000
First Named Inventor	Fikes, John D
Group Art Unit	
Examiner Name	
Attorney Docket Number	018623015720

SER 27 2001

RECEIVED

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard, Copy of the International Search Report
<input checked="" type="checkbox"/> Information Disclosure Statement, 22 References	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Jean M. Lockyer, Ph.D.	Reg No. 44,879
Signature		
Date		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name	
Signature	Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1269350 v1

O I P E
MAILED & CERTIFIED
SEP 24 2001
PATENT & TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

PATENT
Attorney Docket No.: 018623-015720US
Client Reference No.: EPI 0157.20US

On _____

TOWNSEND and TOWNSEND and CREW LLP

By: _____

TECH CENTER 1600/2900

SEP 27 2001

RECEIVED
P#S

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John Fikes et al.

Application No.: 09/583200

Filed: May 30, 2000

For: HLA CLASS I A2 TUMOR
ASSOCIATED ANTIGEN PEPTIDES
AND VACCINE COMPOSITIONS

Examiner:

Art Unit:

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on attached form PTO-SB/08A and SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the International Search Report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and

no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Jean M. Lockyer, Ph.D.
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:adf

SF 1269349 v1



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

S
SEP 25 2001

SEP 27 2007

RECEIVED

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/583200
		Filing Date	May 30, 2000
		First Named Inventor	Fikes, John D
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	018623-015720US
Sheet	1	of	3

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2 of 3

SEP 25 2001

Complete if Known

Application Number	09/583200
Filing Date	May 30, 2000
First Named Inventor	Fikes, John D
Group Art Unit	
Examiner Name	
Attorney Docket Number	018623-015720US

SEP 27 2001

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AE	Bender, et al. "Improved Methods for the Generation of Dendritic Cells from Nonproliferating Progenitors in Human Blood" <i>J. of Immunological Methods</i> (1996) Vol. 196, pp. 121-135.	<input type="checkbox"/>
	AF	Celis, et al. "Epitope Selection and Development of Peptides Based Vaccines to Treat Cancer" <i>Cancer Biology</i> (1995) Vol. 6, pp. 329-336.	<input type="checkbox"/>
	AG	Celis, et al. "Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five-Common HLA-A Alleles" <i>Molecular Immunology</i> (1994) Vol. 31(18), pp. 1423-1430.	<input type="checkbox"/>
	AH	Celis, et al. "Induction of Anti-tumor Cytotoxic T Lymphocytes in Normal Humans Using Primary Cultures and Synthetic Peptide Epitopes" <i>Proc. Natl. Acad. Sci.</i> (March 1994) Vol. 91, pp. 2105-2109.	<input type="checkbox"/>
	AI	Gaugler, et al. "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes" <i>Ludwig Institute for Cancer Research, Brussels Branch</i> (March 1994) Vol. 179(3), pp. 921-930.	<input type="checkbox"/>
	AJ	Kawakami, et al. "Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression" <i>J. of Immunology</i> (1995) Vol. 154, pp. 3961-3968.	<input type="checkbox"/>
	AK	Kawashima, et al. "The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors" <i>Human Immunology</i> (1998) Vol. 59, pp. 1-14.	<input type="checkbox"/>
	AL	Nijman, et al. "p53, A Potential Target for Tumor-directed T Cells" <i>Immunology Letters</i> (1994) Vol. 40, pp. 171-178.	<input type="checkbox"/>
	AM	Parkhurst, et al. "Improved Induction of Melanoma-Reactive CTL with Peptide from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues" <i>J. of Immunology</i> (1996) pp. 2540-2547.	<input type="checkbox"/>
	AN	Ras, et al. "Identification of Potential HLA-A *0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesion Molecule (Ep-CAM) and the Carcinoembryonic Antigen (CEA)" <i>Human Immunology</i> (1997) Vol. 53, pp. 81-89.	<input type="checkbox"/>
	AO	Reynolds, et al. "HLA-Independent Heterogeneity of CD8 ⁺ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients" <i>J. of Immunology</i> (1998) Vol. 161, pp. 6970-6976.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1269346 v1



Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INSTITUTE FOR FORM 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	09/583200
Filing Date	May 30, 2000
First Named Inventor	Fikes, John D
Group Art Unit	
Examiner Name	

TECH CENTER 1600/2900

SEP 27 2001

Attorney Docket Number 018623-015720US

SEP 25 2001

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AP	Rodriguez, et al. "Selective Transport of Internalized Antigens to the Cytosol for MHC Class I Presentation in Dendritic Cells" <i>Nature Cell Biology</i> (October 1999) Vol. 1, pp. 362-368.	<input type="checkbox"/>
	AQ	Rongcun, et al. "Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogenic Carcinomas and Melanomas" "J. of Immunology" (1999) pp. 1037-1044.	<input type="checkbox"/>
	AR	Sette, et al. "HLA Supertypes and Supermotifs: A Functional Perspective on HLA Polymorphism" <i>Immunology</i> (1998) Vol. 10, pp. 478-482.	<input type="checkbox"/>
	AS	Sidney, et al. "Practical, Biochemical and Evolutionary Implications of the Discovery of HLA class I Supermotifs" <i>Immunology Today</i> (1996) Vol. 17(6), pp. 261-266.	<input type="checkbox"/>
	AT	Slingluff, et al. "Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes is Mediated by at least Six Shared Peptide Epitopes" <i>J. of Immunology</i> (April 1993) Vol. 150(7), pp. 2955-2963.	<input type="checkbox"/>
	AU	Tsai, et al "Identification of Subdominant CTL Epitopes of the gp100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells" <i>J. of Immunology</i> (1997) Vol. 158, pp. 1796-1802.	<input type="checkbox"/>
	AV	Watts, Colin "Dendritic Cells Spill the Beans" <i>Nature Cell Biology</i> (October 1999) Vol. 1, pp. E152-E154.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1269346 v1

RECEIVED